People · Operator
Named in public records as an officer, director or promoter · active 2019–2020 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Novus Therapeutics, Inc. | — | Biotechnology | Series D+ | $226.8M | $576.2M | 2019 |
| Reneo Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $159.4M | $519.8M | 2020 |
Gregory Flesher at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Gregory Flesher on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ed Mathers | 1 | 11 |
| Michael Grey | 1 | 10 |
| Campbell Murray | 1 | 9 |
| Erez Chimovits | 1 | 7 |
| John McBride | 1 | 7 |
| Timothy J. Barberich | 1 | 7 |
| Niall O'Donnell | 1 | 7 |
| James Robinson | 1 | 6 |
| Bryan Smith | 1 | 6 |
| Seth L. Harrison | 1 | 4 |
| Campbell A. Murray | 1 | 4 |
| Scott Weiner | 1 | 4 |
| Kenneth Harrison | 1 | 4 |
| Edward T. Mathers | 1 | 3 |
| June Lee | 1 | 3 |
| Cheryl Cohen | 1 | 3 |
| Bali Muralidhar | 1 | 3 |
| Art Pappas | 1 | 3 |
| Reinhard J. Ambros | 1 | 3 |
| David Kessler | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.